According to a recent study conducted by the University of Pennsylvania, the H3N2 antigen component incorporated in the 2021-2022 human influenza vaccine may not be entirely protective.  This is due to a mutation in the current circulatingH3N2 strain since selection for incorporation in the vaccine many months ago.  Although the vaccine now being administered may not be entirely effective in preventing infection with circulating strains of H3N2, the probabilities are that immunity stimulated by the quadrivalent inactivated vaccine will prevent a serious clinical outcome especially in those most vulnerable to seasonal influenza.

By the same token, the two mRNA vaccines against COVID may not protect completely against infection with the Omicron variant that is now competing with the Delta variant in the U.S.

Notwithstanding the possible mismatch between circulating viruses and antibodies stimulated by vaccines, protection from a serious clinical outcome will be provided from a three-course  immunization comprising two priming doses and the essential booster against COVID.

Receiving the current 2021-2022 influenza vaccine is strongly advocated by public health authorities and responsible physicians.  This is especially the case in the elderly or those with predisposing health conditions including obesity, diabetes and heavy tobacco use.  The winter of 2020-2021 was characterized by a low incidence of influenza due in part to masking and social distancing to prevent COVID.  Immunity levels may have waned since 2019 and accordingly vaccination is strongly recommended since the influenza vaccine will partially protect against H3N2 and more effectively against H1N1 and the two strains of influenza B included in the current dose.

Co-morbidity with COVID and seasonal influenza will undoubtedley increase hospital admissions, the need for IC support and deaths. Severe consequences from either or both infections are preventable by vaccination. Time is passing so let us roll up our sleeves!